Veligrotug  (Synonyms: AVE1642; VRDN-001)

Veligrotug (AVE1642) is a selective, fully human IGF-1R antagonist antibody with a K_d value of 0.55 nM for hIGF-1R. Veligrotug blocks the phosphorylation of downstream AKT. Veligrotug is applicable to research related to thyroid eye disease^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

IGF1R/CD221

Veligrotug binds to recombinant hIGF-1R ECD protein with high affinity, with a mean K_d value of 0.55 nM^[2].
Veligrotug (30 min) binds with high affinity to HOCF cells endogenously expressing IGF-1R, with a mean EC₅₀ of 2.41 nM and a mean K_d of 1.85 nM^[2].
Veligrotug (0.46-1000 nM; 1 h) does not inhibit insulin-mediated insulin receptor phosphorylation in HepG2 cells even at concentrations as high as 1000 nM^[2].
Veligrotug (0.008-500 nM; 30 min preincubation on ice) almost completely inhibits the binding of IGF-1 to IGF-1R on FreeStyle 293-F cells at concentrations ≥50 nM^[2].
Veligrotug (0.0001-333 nM; 1 h) completely inhibits IGF-1-mediated AKT phosphorylation in primary HOCF cells at concentrations of 10-30 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Veligrotug (10-50 mg/kg; i.v.; weekly 30-minute infusion; 13 weeks) sustains an approximately 2.5-fold increase in serum IGF-1 concentrations in male and female cynomolgus monkeys throughout the dosing period, while the 2 mg/kg group loses this effect due to anti-drug antibody development in most animals^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3480  [NCBI]

P08069

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

147.7 kDa

2728655-31-8

Liquid

Colorless to light yellow

[Veligrotug]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow cytometric analysis of 1X10⁶ MCF-7 cells labeling Veligrotug (HY-P990084, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Turbin R, et al. Veligrotug (VRDN-001), a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease (TED): THRIVE Phase 3 Efficacy and Safety Topline Results[J]. Investigative Ophthalmology & Visual Science, 2025, 66(8): 4302-4302.

  [2]. Kaplan R, et al. Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs. 2025;17(1):2585616.